Montelukast improves asthma control in asthmatic children maintained on inhaled corticosteroids

Annals of Allergy, Asthma and Immunology

Volumn 91, Issue 1, 2003, Pages 49-54

  Phipatanakul, Wanda ^a   Greene, Charles ^b   Downes, Sandra J ^a   Cronin, Beth ^a   Eller, T J ^c   Schneider, Lynda C ^a   Irani, Anne Marie ^b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CORTICOSTEROID; FLUNISOLIDE; MONTELUKAST; PLACEBO; TRIAMCINOLONE;

ADOLESCENT; ARTICLE; ASTHMA; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CONTROL; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FORCED EXPIRATORY VOLUME; HEADACHE; HUMAN; LUNG FUNCTION TEST; MALE; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINORRHEA; SIDE EFFECT; SPIROMETRY; TREATMENT OUTCOME;

EID: 0042344920     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)62058-3     Document Type: Article

References (21)

1. National Institutes of Health. National Heart, Lung, and Blood Institute. Guidelines for Diagnosis and Management of Asthma: Expert Panel Report 2. Bethesda, MD: NIH; 1997:45-46.
2. Greening AP, Ind PW, Northfield M, Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group. Lancet. 1994;344:219-224.
3. Pauwels RA, Lofdahl CG, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corficosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med. 1997;337:1405-1411.
4. Fireman P. Combination of inhaled corticosteroids plus other medications in the management of moderate to severe persistent asthma. Allergy Asthma Proc. 2000;21:315-322.
5. Simons FE, Villa JR, Lee BW, et al. Montelukast added to budesonide in children with persistent asthma: a randomized, double-blind, crossover study. J Pediatr. 2001;138:694-698.
6. Noonan MJ, Chervinsky P, Brandon M, et al. Montelukast, a potent leukotriene receptor antagonist, causes dose-related improvements in chronic asthma. Montelukast Asthma Study Group. Eur Respir J. 1998;11:1232-1239.
7. Reiss TF, Chervinsky P, Dockhorn RJ, Shingo S, Seidenberg B, Edwards TB. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Montelukast Clinical Research Study Group. Arch Intern Med. 1998;158:1213-1220.
8. Knorr B, Matz J, Bernstein JA, et al. Montelukast for chronic asthma in 6- to 14-year-old children: a randomized, double-blind trial. Pediatric Montelukast Study Group. JAMA. 1998;279:1181-1186.
9. Riddick CA, Ring WL, Baker JR, Hodulik CR, Bigby TD. Dexamethasone increases expression of 5-lipoxygenase and its activating protein in human monocytes and THP-1 cells. Eur J Biochem. 1997;246:112-118.
10. Salvi SS, Krishna MT, Sampson AP, Holgate ST. The anti-inflammatory effects of leukotriene-modifying drugs and their use in asthma. Chest. 2001;119:1533-1546.
11. Laviolette M, Malmstrom K, Lu S, et al. Montelukast added to inhaled beclomethasone in treatment of asthma. Montelukast/ Beclomethasone Additivity Group. Am J Respir Crit Care Med. 1999;160:1862-1868.
12. Lofdahl CG, Reiss TF, Leff JA, Israel E, Noonan MJ, et al. Randomised, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients. BMJ. 1999;319:87-90.
13. Santanello NC, Barber BL, Reiss TF, Friedman BS, Juniper EF, Zhang J. Measurement characteristics of two asthma symptom diary scales for use in clinical trials. Eur Respir J. 1997;10:646-651.
14. Kundu S, Noonan N, Friedman BS, Reiss TF, Lett JA. Use of a composite clinical score allows safe tapering of inhaled corticosteroids (ICS) in asthmatic patients. Am J Respir Crit Care Med. 1997;155:A352.
15. Tamaoki J, Kondo M, Sakai N, et al. Leukotriene antagonist prevents exacerbation of asthma during reduction of high-dose inhaled corticosteroid. The Tokyo Joshi-Idai Asthma Research Group. Am J Respir Crit Care Med. 1997;155:1235-1240.
16. Christian Virchow J, Prasse A, Naya I, Summerton L, Harris A. Zafirlukast improves asthma control in patients receiving high-dose inhaled corticosteroids. Am J Respir Crit Care Med. 2000;162:578-585.
17. Dahlen SE, Malmstrom K, Nizankowska E, et al. Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: a randomized, double-blind, placebo-controlled trial. Am J Respir Crit Care Med. 2002;165:9-14.
18. Tomita K, Hashimoto K, Matsumoto S, et al. Pranlukast allows reduction of inhaled steroid dose without deterioration in lung function in adult asthmatics [in Japanese]. Arerugi. 1999;48:459-465.
19. Tohda Y, Fujimura M, Taniguchi H, et al. Leukotriene receptor antagonist, montelukast, can reduce the need for inhaled steroid while maintaining the clinical stability of asthma patients. Clin Exp Allergy. 2002;32:1180-1186.
20. Cumming RG, Mitchell P, Leeder SR. Use of inhaled corticosteroids and the risk of cataracts. N Engl J Med. 1997;337:8-14.
21. Hanania NA, Chapman KR, Kesten S. Adverse effects of inhaled corticosteroids. Am J Med. 1995;98:196-208.